Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.

ABSTRACT: Acute myeloid leukemia (AML) in older patients has a poor prognosis, low complete remission (CR) rates, and poor overall survival (OS). Preclinical studies have shown synergistic effects of epigenetic priming with hypomethylating agents followed by cytarabine. Based on these data, we hypothesized that an induction regimen using epigenetic priming with decitabine, followed by cytarabine would be effective and safe in older patients with previously untreated AML. Here, we conducted a phase 2 trial in which older patients with previously untreated AML received an induction regimen consisting of 1 or 2 courses of decitabine 20 mg/m² intravenously (IV) for 5 days followed by cytarabine 100 mg/m² continuous IV infusion for 5 days. Forty-four patients (median age 76 years) w

SUBMITTER: Im A 

PROVIDER: S-EPMC11552450 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature